Calidi Biotherapeutics, Inc. CLDI
AMEX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.50% | -24.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.88% | -6.25% | |||
| Operating Income | 0.88% | 6.25% | |||
| Income Before Tax | -1.24% | -1.06% | |||
| Income Tax Expenses | 25.00% | 300.00% | |||
| Earnings from Continuing Operations | -1.27% | -1.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.27% | -1.28% | |||
| EBIT | 0.88% | 6.25% | |||
| EBITDA | 1.30% | -19.66% | |||
| EPS Basic | 57.15% | 24.76% | |||
| Normalized Basic EPS | 53.94% | 34.06% | |||
| EPS Diluted | 57.15% | 24.76% | |||
| Normalized Diluted EPS | 53.94% | 34.06% | |||
| Average Basic Shares Outstanding | 119.77% | 44.75% | |||
| Average Diluted Shares Outstanding | 119.77% | 44.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||